Tom Chang
Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Tom Chang is a Professor at Utah State University in the United States. His research focuses on biochemistry and pharmacology, specifically on topics such as mesobiliverdin-related products, antibiotic alternatives in animal health, and the development of connexin hemichannel inhibitors. Through his recent publications, he explores innovative solutions in both microalgal applications and antifungal drug synthesis.
Articles (5)
Year:
2025
Year:
2024
Background: Connexins (Cxs) are proteins that help cells to communicate with the extracellular media and with the cytoplasm of neighboring cells. Despite their importance in several human physiological and pathological conditions, their pharmacology is very poor. In the last decade, some molecules derived from aminoglycosides have been developed as inhibitors of Cxs hemichannels. However, these studies have been performed in E. coli, which is a very simple model. Therefore, our main goal is to test whether these molecules have similar effects in mammalian cells. Methods: We transfected HeLa cells with the human Cx46tGFP and characterized the effect of a kanamycin-derived molecule (KI04) on Cx46 hemichannel activity by time-lapse recordings, changes in phosphorylation by Western blot, localization by epifluorescence, and possible binding sites by molecular dynamics (MD). Results: We observed that kanamycin and KI04 were the most potent inhibitors of Cx46 hemichannels among several aminoglycosides, presenting an IC50 close to 10 μM. The inhibitory effect was not associated with changes in Cx46 electrophoretic mobility or its intracellular localization. Interestingly, 5 mM DTT did not reverse KI04 inhibition, but the KI04 effect completely disappeared after washing out KI04 from the recording media. MD analysis revealed two putative binding sites of KI04 in the Cx46 hemichannel. Results: These results demonstrate that KI04 could be used as a Cx46 inhibitor and could help to develop future selective Cx46 inhibitors.
Year:
2023
Year:
2023
Year:
2021
Collaborators (2)
Jon Y. Takemoto
Emeritus Professor
Utah State University
Mauricio A. Retamal
Texas Tech University Health Sciences Center
Make your next move.
Prepare your application
Review drafts before you send them.